List view / Grid view
Thermo Fisher Scientific Inc., the world leader in serving science, today announced a new upgrade program that includes the donation of reconditioned Thermo Scientific NanoDrop 1000 spectrophotometers to academic institutions in developing countries.
3 May 2011 | By OgilvyHealthPR
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.1 The FDA has approved linagliptin as a monotherapy…
2 May 2011 | By Cephalon, Inc.
Teva will acquire all of the outstanding shares of Cephalon for a total enterprise value of approximately $6.8 billion...
28 April 2011 | By College Hill Ltd
GE Healthcare, today announced it has reached an agreement to acquire Applied Precision, Inc...
Thermo Fisher Scientific Inc., the world leader in serving science, today announced a free summer symposium presenting the latest developments in laboratory solutions.
28 April 2011 | By Johnson & Johnson
Johnson & Johnson and Synthes announce definitive merger agreement to create world’s most comprehensive orthopaedics business...
28 April 2011 | By POZEN Inc.
AstraZeneca and POZEN have filed a patent infringement lawsuit against Dr. Reddy's relating to VIMOVO(TM)...
27 April 2011 | By Eli Lilly & Company
Collaboration combines companies' expertise in neuroscience and targeted drug delivery...
27 April 2011 | By GlaxoSmithKline
The FDA has approved Lamictal® XR™ (lamotrigine) Extended-Release Tablets for conversion to monotherapy...
27 April 2011 | By Decision Resources
Decision Resources suggests that growth will be driven by the launches of premium-priced therapies...
26 April 2011 | By Daiichi Sankyo
LIXIANA® (Edoxaban) is a direct oral factor Xa inhibitor for the prevention of venous thromboembolism...
26 April 2011 | By
To promote leading edge cell-based and biochemical GPCR and Kinase assays to the European community...
25 April 2011 | By Pfizer Inc.
Pfizer has commented on an abstract concerning the ORAL Sync Phase 3 study of tofacitinib in patients with rheumatoid arthritis...
22 April 2011 | By Idera Pharmaceuticals, Inc.
Delay is based on preliminary data from a 26-week nonclinical toxicology study...
22 April 2011 | By Sanofi Pasteur
Sanofi Pasteur announces that the FDA has granted licensure to expand the indication for its meningococcal conjugate vaccine...
